TraczewskiMMGoldmanDAMurphyP. In vitro activity of rifampin in combination with oxacillin against. Antimicrob Agents Chemother1983; 23: 571–6.
2.
ZinnerSHLagastHKlasterskyJ. Antistaphylococcal activity of rifampin with other antibiotics. J Infect Dis1981; 144: 365–71.
3.
Van Der AuweraPKlasterskyJ. In vitro study of the combination of rifampin with oxacillin against. Rev Infect Dis1983; 5: S509–14.
4.
WatanakunakornCTisoneJC. Antagonism between nafcillin or oxacillin and rifampin against. Antimicrob Agents Chemother1982; 22: 920–2.
5.
NordenCW. Experimental osteomyelitis IV. Therapeutic trials with rifampin alone and in combination with gentamicin, sisomicin, and cephalothin. J Infect Dis1975; 132: 493–9.
6.
NordenCWKeketiE. Treatment of experimental staphylococcal osteomyelitis with rifampin and trimethoprim, alone and in combination. Antimicrob Agents Chemother1980; 17: 591–4.
7.
NordenCWShafferM. Treatment of experimental osteomyelitis due to Staphylococcus aureus with vancomycin and rifampin. J Infect Dis1983; 147: 352–7.
8.
NordenCW. Experimental chronic staphylococcal osteomyelitis in rabbits: treatment with rifampin alone and in combination with other antimicrobial agents. Rev Infect Dis1983; 5: S491–4.
BeamTR. Sequestration of staphylococci at an inaccessible focus. Lancet1979; 2: 227–8.
11.
Van Der AuweraPMeunier-CarpenterFKlasterskyJ. Clinical study of combination therapy with oxacillin and rifampin for staphylococcal infections. Rev Infect Dis1983; 5: S515–22.
12.
Van Der AuweraPThysJPMeunier-CarpenterFKlasterskyJ. The combination of oxacillin with rifampin in staphylococcal infections: a review of laboratory and clinical studies of Institut Jules Bordet. J Antimicrob Chemother1984; 13 (suppl C): 31–42.
13.
LoboMCMandellGL. Treatment of experimental staphylococcal infection with rifampin. Antimicrob Agents Chemother1972; 2: 195–200.
14.
MandellGLVestTK. Killing of intraleukocytic Staphylococcus aureus by rifampin: in vitro and in vivo studies. J Infect Dis1972; 25: 486–90.
15.
FairbanksDNShimizuHWarfieldD. Unilateral vestibular ablation with streptomycin. Arch Otolaryngol1971; 93: 590–6.
16.
GraybielASchuknechtHFFreglyAR. Streptomycin in Meniere's disease. Arch Otolaryngol1967; 85: 156–70.
17.
FowlerEP. Streptomycin treatment of vertigo. Trans Am Acad Ophthalmol Otolaryngol1948; 52: 239–301.
18.
SingletonEFSchuknectHF. Streptomycin sulfate in the management of Meniere's disease. Otolaryngol Clin North Am1968; 1: 531–9.
19.
AppelGBNeuHC. Gentamicin in 1978. Ann Intern Med1978; 89: 528–38.
20.
JaoRLJacksonGG. Gentamicin sulfate, new antibiotic against gram-negative bacilli. JAMA1967; 189: 817–22.
21.
BeckCSchmidtCL. 10 years of experience with intratympanically applied streptomycin (gentamicin) in the therapy of Morbus Meniere. Arch Otorhinolaryngol1978; 221: 149–52.
22.
Van MarionWFVan Der MeerJWMKalffMWSchichtSM. Ototoxicity of erythromycin (letter). Lancet1978; 2: 214–5.
EckmanMRJohnsonTRiessR. Partial deafness after erythromycin (letter). N Engl J Med1975; 292: 649.
25.
KanferADanielFVigiralPMeryJPHaguetJF. Surdite transitoire chez des insuffisant renaux tractes par l'erythromycine (letter). Nouv Presse Med1979; 8: 2283–4.
26.
KrobothPDMcNeilMAKreegerADominguezJRaultR. Hearing loss and erythromycin pharmacokinetics in a patient receiving hemodialysis. Arch Intern Med1983; 143: 1263–6.
27.
TaylorRScholfieldISRamosJMBintAJWardMK. Ototoxicity of erythromycin in peritoneal dialysis patients (letter). Lancet1981; 2: 935–6.
28.
QuinnanGVMcCabeWR. Ototoxicity of erythromycin. Lancet1978; 1: 1160–1.
MeryJPKanferA. Ototoxicity of erythromycin in patients with renal insufficiency (letter). N Engl J Med1979; 301: 944.
31.
MintzUAmirJPinkhasJDevriesA. Transient perceptive deafness after erythromycin (letter). JAMA1973; 225: 1122–3.
32.
KarmodyCSWeinsteinLW. Reversible sensorineural hearing loss with intravenous erythromycin lactobionate. Ann Otol1977; 86: 9–11.
33.
BecknerRRGaatzNHughesJPFarricyFA. Ototoxicity of erythromycin gluceptate. Am J Obstet Gynecol1981; 139: 738–9.
34.
LornoyWSteyaertJ. Ototoxicity of erythromycin lactobionate. Acta Clinica Belgia1979; 34: 111.
35.
ErrickJKHyrcink-FlaskaLThiesH. Probable erythromycin ototoxicity. Drug Intell Clin Pharm1980; 14: 623–5.
36.
UmsteadSNeumannKH. Erythromycin ototoxicity and acute psychotic reaction in cancer patients with hepatic dysfunction. Arch Intern Med1986; 146: 897–9.
37.
American Society of Hospital Pharmacists. American Hospital Formulary Service. Drug Information. Bethesda, MD: American Society of Hospital Pharmacists, 1986.
38.
KuninCMFinlandM. Persistence of antibiotics in blood of patients with acute renal failure. J Clin Invest1959; 35: 1509–19.
39.
BennettWMMutherRSParkerRA. Drug therapy in renal failure: dosing guidelines for adults. Ann Intern Med1980; 93: 62–89.
40.
StuppHKupperKLaglerFSousHQuanteM. Inner ear concentrations and ototoxicity of different antibiotics in local and systemic application. Audiology1972; 12: 350–63.
41.
KrobothPDBrownALyonJAKrobothFJJuhlRP. Pharmacokinetics of single dose erythromycin in normal and alcoholic liver disease subjects. Antimicrob Agents Chemother1982; 21: 135–40.
42.
SchwartzHJ. Sensitivity to ingested metabisulfite: variations in clinical presentation. J Allergy Clin Immunol1983; 71: 487–9.
43.
BakerGJCollettPAllenDH. Bronchospasm induced by metabisulphite-containing foods and drugs. Med J Aust1981; 2: 614–6.
44.
WitekTJSchachterEN. Detection of sulfur dioxide in bronchodilator aerosols. Chest1984; 86: 592–4.
45.
KoepkeJWSelnerJCDunhillAL. Presence of sulfur dioxide in commonly used bronchodilator solutions. J Allergy Clin Immunol1983; 72: 504–8.
46.
TwarogFJLeungDY. Anaphylaxis to a component of isoetharine (sodium bisulfite). JAMA1982; 248: 2030–1.
47.
TownsSJMellisCM. Role of acetyl salicylic acid and sodium metabisulfite in chronic childhood asthma. Pediatrics1984; 73: 631–7.
48.
BethelRAEpsteinJSheppardDNadelJABousheyHA. Sulfur dioxide-induced bronchoconstriction in freely breathing, exercising, asthmatic subjects. Am Rev Respir Dis1983; 128: 987–90.
49.
SheppardDEschenbacherWLBousheyHABethelRA. Magnitude of the interaction between the bronchomotor effects of sulfur dioxide and those of dry (cold) air. Am Rev Respir Dis1984; 130: 52–5.
50.
SheppardDWongWSUeharaCFNadelJABousheyHA. Lower threshold and greater bronchomotor responsiveness of asthmatic subjects to sulfur dioxide. Am Rev Respir Dis1980; 122: 873–8.
51.
SimonRAGreenLStevensonDD. The incidence of ingested metabisulfite sensitivity in an asthmatic population (abstract). J Allergy Clin Immunol1982; 69: 118.
DeloheryJSimmulRCastleWDAllenDH. The relationship of inhaled sulfur dioxide reactivity to ingested metabisulfite sensitivity in patients with asthma. Am Rev Respir Dis1984; 130: 1027–32.
54.
SnashallPDBaldwinC. Mechanisms of sulphur dioxide induced bronchoconstriction in normal and asthmatic man. Thorax1982; 37: 118–23.
